See discussions, stats, and author profiles for this publication at: https://www.researchgate.

net/publication/343303270

PRG-1801：A NMPA approved CAR-T with potential utility for multiple

myeloma Rational for the development of PRG-1801 for MM

Presentation · July 2020

CITATIONS READS

0 484

1 author:

Allen Li
PREGENEN
1 PUBLICATION   0 CITATIONS   

SEE PROFILE

All content following this page was uploaded by Allen Li on 30 July 2020.

The user has requested enhancement of the downloaded file.

 PRG-1801：A NMPA approved CAR-T with potential utility for multiple myeloma

 PRG-1801 has received IND clearance by • Modified structure complying with FDA safety requirement
NMPA for clinical trail and is filing in FDA • Lentivirus with Serum-free culture
 Strong safety database in MM indication • Sophisticated IPR protection
 Low levels of CRS • Shrank tumors in nearly 88% of relapsed multiple myeloma
 Distinct MOA to other CAR-Ts patients and eliminated them in 56%
 Integrated R&D platform: PRG CGT + Rational for the development of PRG-1801 for MM
Naffibody Platform 1. Anti-BCMA VHH specifically designed for CAR-T
- High specificity and affinity
- Less cross-pairing effect
2. Stable manufacturing with low cost
- Optimized plasmid design
- Stable and high-yield vector production system.
- Self-developed QC methods with low cost
3. Superior clinical safety and efficacy
- Low frequence and severity of AE
- Long duration of efficacy

View publication stats